Turning Point Benefit Group, Inc. Fate Therapeutics Inc Transaction History
Turning Point Benefit Group, Inc.
- $166 Billion
- Q3 2025
A detailed history of Turning Point Benefit Group, Inc. transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Turning Point Benefit Group, Inc. holds 14 shares of FATE stock, worth $13. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14Holding current value
$13% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding FATE
# of Institutions
155Shares Held
81.4MCall Options Held
46.4KPut Options Held
17.5K-
Redmile Group, LLC San Francisco, CA12.9MShares$12.4 Million1.79% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$9.71 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.8MShares$8.45 Million0.0% of portfolio
-
Wilshire Advisors LLC Santa Monica, CA8.49MShares$8.15 Million27.71% of portfolio
-
Johnson & Johnson New Brunswick, NJ3.38MShares$3.24 Million1.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $93.1M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...